Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes
Authors: Udaya M. Kabadi
Journal: Annals of Internal Medicine (2021)

LettersJanuary 2021Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 DiabetesUdaya M. Kabadi, MDUdaya M. Kabadi, MDBroadlawns Medical Center, University of Iowa, Des Moines, IowaAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L20-1277 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:I concur with Tsapas and colleagues that comparisons of drugs for glycemic efficacy, safety, and other outcomes are best shown on administration in drug-naive participants. Comparative glycemic efficacy may be even better validated by expressing the percentage decline rather than point fall in baseline hemoglobin A1c (HbA1c) unless the baseline HbA1c levels for individual agents are not significantly different and daily doses of agents are equivalent. Unfortunately, most comparative trials between newer and established drugs (such as metformin and sulfonylureas) have been done with maximum recommended daily doses of newer drugs but minimal to half the maximum ...References1. Tsapas A, Avgerinos I, Karagiannis T, et al. Comparative effectiveness of glucose-lowering drugs for type 2 diabetes. A systematic review and network meta-analysis. Ann Intern Med. 2020;173:278-86. doi:10.7326/M20-0864 LinkGoogle Scholar2. Kabadi UM. New oral diabetes drugs are more effective than older agents: real or a fraud? J Diabetes Metab Disord Control. 2016;3:67-9. doi:10.15406/jdmdc.2016.03.00071 Google Scholar3. Kabadi UM. United Kingdom Prospective Diabetes Study: a different perspective. Endocr Pract. 2002 Jan-Feb;8:61-4. [PMID: 11939763] CrossrefMedlineGoogle Scholar4. Kabadi UM. Cardiovascular outcome trials in type 2 diabetes: reliable or biased! World Journal of Pharmaceutical and Medical Research. 2017;3:33-5. Google Scholar5. de Jong M, Woodward M, Peters SAE. Diabetes, glycated hemoglobin, and the risk of myocardial infarction in women and men: a prospective cohort study of the UK Biobank. Diabetes Care. 2020;43:2050-9. [PMID: 32651263] doi:10.2337/dc19-2363 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Broadlawns Medical Center, University of Iowa, Des Moines, IowaDisclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L20-1277. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoComparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes Apostolos Tsapas , Ioannis Avgerinos , Thomas Karagiannis , Konstantinos Malandris , Apostolos Manolopoulos , Panagiotis Andreadis , Aris Liakos , David R. Matthews , and Eleni Bekiari Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes Apostolos Tsapas , Thomas Karagiannis , Ioannis Avgerinos , David R. Matthews , and Eleni Bekiari Metrics January 2021Volume 174, Issue 1Page: 140KeywordsDiureticsDrug administrationDrug safetyDrugsFallsHbA1cHeart failureMyocardial infarctionSafetyType 2 diabetes ePublished: 19 January 2021 Issue Published: January 2021 Copyright & PermissionsCopyright © 2021 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...